Veraxa Biotech AG (VRXA)
NasdaqGM: VRXA
· Precio en tiempo real · USD
1.86
-0.01 (-0.53%)
Al cierre: Aug 17, 2026, 3:55 PM
1.84
-1.06%
Premercado: 4:35 AM
Veraxa Biotech AG (VRXA) Stock Price, Analysis & Data
-0.53% (1D)
| Precio de compra | 1.85 |
| Capitalización de mercado | 263.02M |
| Ingresos (TTM) | n/a |
| Beneficio neto (TTM) | n/a |
| Beta | n/a |
| EPS (TTM) | -0.57 |
| Ratio PER (TTM) | n/a |
| Adelante PE | n/a |
| P/B (TTM) | n/a |
| P/S (TTM) | n/a |
| Earnings Date | n/a |
| Precio de venta | 1.9 |
| Volumen | 47,185 |
| Volumen medio (20D) | 461,519 |
| Abierto | 1.87 |
| Anterior Cerrar | 1.87 |
| Rango del día | 1.81 - 1.88 |
| Rango de 52 semanas | 1.70 - 27.36 |
| analista | n/a |
| Precio objetivo | n/a |
| Dividendos | n/a |
| Fecha ex dividendo | n/a |
Acerca de VRXA
VERAXA Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation. Its product pipeline includes drug candidates such as ADCs and BITACs, with some in clinical development, and it provides partn...
Industria Biotechnology
Sector Healthcare
IPO Fecha Sep 30, 2024
Empleados n/a
Bolsa de Valores NasdaqGM
Símbolo bursátil VRXA
Sitio web https://www.veraxa.com
Desempeño financiero
En 2025, los ingresos de Veraxa Biotech fueron 23.43K, un aumento de undefined% en comparación con 0 del año anterior. Las ganancias fueron -66.61M, un aumento de 136.78%.
Estados financieros
